Health Canada Issues Resverlogix Authorization to Begin Immediate Clinical Studies of Apabetalone for COVID-19 Resverlogix Plans to Emulate the Pfizer and Moderna Models of Rapid Parallel Development use
April 12, 2021 08:00 ET | Source: Resverlogix Corp Resverlogix Corp Calgary, Alberta, CANADA
CALGARY, Alberta, April 12, 2021 (GLOBE NEWSWIRE) Resverlogix Corp. ( Resverlogix ) (TSX:RVX) is pleased to announce that it has successfully received its desired “No Objection Letter” from Health Canada. It has approved the COVID-19 Clinical Trial Application for apabetalone. The planned Phase 2 trial will be an open-label study evaluating the safety and efficacy of oral apabetalone, in combination with standard of care for patients hospitalized with COVID-19. “Today’s exciting announcement is an important step in advancing apabetalone’s clinical development as a potentially highly effective therapeutic for CO
New Published Evidence of Apabetalone s Beneficial Effects on COVID-19 Toronto Stock Exchange:RVX
globenewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from globenewswire.com Daily Mail and Mail on Sunday newspapers.
New Published Evidence of Apabetalone s Beneficial Effects on COVID-19 Apabetalone treatment reduces SARS-CoV-2 infectivity and completely prevents cardiac damage in a cytokine-storm model
financialpost.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from financialpost.com Daily Mail and Mail on Sunday newspapers.
Article content
CALGARY, Alberta, Jan. 18, 2021 (GLOBE NEWSWIRE) Resverlogix Corp. (“Resverlogix”, or the “Corporation”) (TSX:RVX) today announced that on January 28
th, 2021 at 10:00 am MT, it will be hosting a webcast and conference call for the purpose of updating stakeholders regarding three key areas:
Closing details of the previously announced private placement by Sheikh Abdulgader Aboud Baeshen, President and CEO of Baeshen Trade, Abdulgader Baeshen Co.,
BETonMACE2 design upgrades and partnering options, and
COVID-19 trial update and apabetalone’s strong antiviral effect
For those wishing to join the January 28
th event, it is highly recommended to access the webcast over the Internet using the following LINK.